Be a part of 6th International Meeting on Breast Cancer & Therapies

Early detection remains an important component of breast cancer management and can influence treatment options and patient outcomes. This session will examine advances in screening, diagnostic imaging, risk assessment, and early-stage disease identification. Experts will discuss emerging technologies and multidisciplinary diagnostic approaches, including mammography, ultrasound, MRI, digital imaging, and artificial intelligence-assisted interpretation.

• Track 2-1: Advanced breast imaging and screening
• Track 2-2: AI-assisted diagnosis and detection
• Track 2-3: Risk assessment and early-stage breast cancer

Advances in genomics and molecular biology are providing deeper insights into breast cancer development, progression, and treatment response. This session will focus on hereditary and acquired genetic alterations, molecular subtypes, tumor biomarkers, and emerging diagnostic technologies. Presentations will examine how genomic information and biomarker analysis can support risk assessment, prognosis, treatment selection, and monitoring of disease.

• Track 3-1: Breast cancer genomics and hereditary mutations
• Track 3-2: Liquid biopsy and circulating tumor DNA
• Track 3-3: Predictive and prognostic biomarkers

Targeted therapies have expanded treatment options for patients with specific molecular characteristics of breast cancer. This session will explore developments in HER2-directed therapies, CDK4/6 inhibitors, antibody-drug conjugates, and other pathway-specific treatments. Discussions will address emerging therapeutic combinations, treatment optimization, mechanisms of action, and strategies for managing resistance while improving outcomes across different breast cancer subtypes.

• Track 4-1: HER2-targeted therapies and antibody-drug conjugates
• Track 4-2: CDK4/6 and pathway-directed therapies
• Track 4-3: Emerging targeted treatment strategies

Immunotherapy has become an important area of research in breast cancer, particularly for selected advanced and triple-negative disease. This session will examine immune checkpoint inhibitors, tumor immune microenvironments, predictive biomarkers, and combination approaches. Researchers and clinicians will discuss current evidence, treatment challenges, immune-related considerations, and emerging strategies aimed at improving the effectiveness of immune-based therapies.

• Track 5-1: Immune checkpoint inhibitors
• Track 5-2: Tumor microenvironment and immune biomarkers
• Track 5-3: Combination immunotherapy approaches

Triple-negative breast cancer presents distinctive biological and therapeutic challenges because of the absence of hormone receptor and HER2 expression. This session will explore advances in systemic treatment, immunotherapy, antibody-drug conjugates, molecular classification, and emerging targeted approaches. Discussions will also address treatment resistance, disease recurrence, clinical trials, and opportunities to improve outcomes for patients with TNBC.

• Track 6-1: Emerging therapies for TNBC
• Track 6-2: Immunotherapy and antibody-drug conjugates
• Track 6-3: Treatment resistance and recurrence

Surgical management continues to evolve through improvements in breast-conserving procedures, oncoplastic techniques, reconstruction, and minimally invasive approaches. This session will discuss contemporary surgical strategies designed to achieve effective cancer control while considering functional and aesthetic outcomes. Topics will also include axillary management, sentinel lymph node procedures, neoadjuvant therapy considerations, and multidisciplinary decision-making in breast cancer surgery.

• Track 7-1: Breast-conserving and oncoplastic surgery
• Track 7-2: Reconstruction and surgical innovation
• Track 7-3: Sentinel lymph node and axillary management

Modern radiation oncology is increasingly focused on delivering effective treatment while minimizing exposure to healthy tissues. This session will explore advances in breast radiotherapy, including hypofractionation, image-guided techniques, partial-breast irradiation, and treatment planning technologies. Discussions will address patient selection, radiation safety, integration with systemic therapy, and emerging approaches for different stages and subtypes of breast cancer.

• Track 8-1: Hypofractionation and partial-breast irradiation
• Track 8-2: Image-guided and precision radiotherapy
• Track 8-3: Radiation strategies in advanced disease

Management of metastatic breast cancer requires individualized and multidisciplinary approaches that consider disease biology, previous treatment, metastatic sites, and patient priorities. This session will address therapeutic strategies for advanced disease, including bone, liver, lung, and brain metastases. Experts will discuss treatment sequencing, emerging systemic therapies, management of progression, resistance, symptoms, and approaches supporting quality of life.

• Track 9-1: Management of brain and visceral metastases
• Track 9-2: Treatment sequencing and therapeutic resistance
• Track 9-3: Multidisciplinary care in advanced breast cancer

Clinical research plays a central role in evaluating new breast cancer therapies and translating laboratory discoveries into patient care. This session will examine clinical trial design, novel drug development, translational research, real-world evidence, and emerging treatment combinations. Discussions will also focus on mechanisms of therapeutic resistance and strategies being investigated to overcome resistance and improve treatment durability.

• Track 10-1: Innovative clinical trial design
• Track 10-2: Novel drug development and translational research
• Track 10-3: Mechanisms and management of treatment resistance

Survivorship extends beyond completion of active treatment and includes physical, psychological, social, and long-term health needs. This session will explore comprehensive survivorship care, rehabilitation, recurrence monitoring, lifestyle interventions, psychosocial support, fertility, sexual health, and management of treatment-related effects. Discussions will emphasize patient-centered approaches designed to support long-term well-being and quality of life following breast cancer treatment.

• Track 11-1: Long-term survivorship and follow-up care
• Track 11-2: Rehabilitation and treatment-related effects
• Track 11-3: Psychosocial health, fertility and quality of life

Breast cancer prevention and equitable access to early detection and effective treatment remain important global health priorities. This session will explore hereditary risk, lifestyle factors, risk-reduction strategies, genetic counseling, screening access, and disparities in cancer care. Discussions will consider differences in healthcare resources and outcomes across populations and approaches to strengthening prevention, awareness, diagnosis, and treatment worldwide.

• Track 12-1: Risk assessment and hereditary cancer prevention
• Track 12-2: Lifestyle interventions and risk reduction
• Track 12-3: Global disparities and equitable breast cancer care